10-K: Establishment Labs Reports 2023 Results, Expands Manufacturing and Product Reach

Establishment Labs' 2023 annual report highlights a modest revenue increase, ongoing losses, and strategic expansions in manufacturing and product availability.

Summary

• Establishment Labs reported a revenue of $165.2 million for 2023, a 2.2% increase from $161.7 million in 2022.
• The company experienced a net loss of $78.5 million in 2023, compared to a net loss of $75.2 million in 2022.
• As of December 31, 2023, the company's accumulated deficit was $360.1 million, and cash balance was $40.0 million.
• The company launched Motiva Implants in China and completed the first procedure with the Motiva Flora SmoothSilk Tissue Expander in the United States in January 2024.
• A securities purchase agreement was entered into, selling 2 million common shares and pre-funded warrants for $50 million in gross proceeds.
• The first phase of the Sulym Innovation Campus was opened in July 2023, adding 100,000 square feet of manufacturing space with an estimated capacity of 730,000 units per year.
• The company received NMPA approval in China for Motiva Implants, FDA 510(k) clearance for the Motiva Flora SmoothSilk Tissue Expander, and CE mark approval for several other products in November 2023.
• A two-year clinical study for Mia Femtech was completed in October 2023, showing positive results for breast augmentation without general anesthesia.
• The company launched Zen, a new generation of passive RFID technology, in select geographies in October 2023.
• In April 2023, the company issued 1,165,000 common shares in an underwritten public offering for net proceeds of approximately $84.6 million.
• The final module of the clinical trial for Motiva Implants in the United States was submitted to the FDA in February 2023.
• The company amended its Credit Agreement in February 2024, modifying access conditions, commitment termination dates, and interest rates.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in product launches and regulatory approvals, the increasing losses and reliance on capital raises indicate financial challenges. The company is making progress but faces significant hurdles.

Positives

• The company has a strong focus on product innovation and patient safety.
• The company has a dynamic worldwide sales platform.
• The company has a proven management team with expansive industry experience.
• The company has proprietary internal manufacturing processes and capabilities.
• The company has an extensive suite of complementary products and services.
• The company has a patient-centric innovative implant technologies.

Negatives

• The company has incurred losses since inception and expects to continue to incur losses for the foreseeable future.
• The company has a limited operating history in the United States.
• The company relies on a single-source supplier for medical-grade silicone.
• The company faces intense competition from larger companies with greater resources.
• The company is subject to risks associated with pandemics, epidemics or other public health crises.
• The company has significant exposure to the economic and political situations in emerging market countries.

Risks

• Unfavorable global economic conditions could adversely affect the business.
• The clinical trial process is lengthy and expensive with uncertain outcomes.
• The FDA or similar regulatory authority may not approve the company's products.
• The company may fail to maintain and develop its direct sales force.
• The company may be unable to educate clinicians on the safe and effective use of its products.
• The company may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets.
• The company's business depends on maintaining its brand and ongoing customer demand.
• The company may fail to compete effectively against its competitors.
• Any disruption at the company's existing facilities could adversely affect the business.
• The company relies on a single-source, third-party supplier for medical-grade long-term implantable silicone.
• The company has significant exposure to the economic and political situations in emerging market countries.
• Adverse developments affecting the financial services industry could adversely affect the company's liquidity and financial performance.
• The company's results of operations could be affected by fluctuations in currency rates.
• Negative publicity concerning the company's products or its competitors' products could harm the company's reputation.
• The medical device industry is characterized by patent litigation.

Future Outlook

The company expects to continue investing in manufacturing capacity, marketing, customer service, and sales force in multiple geographies to promote the use of its Motiva Implants. This expansion may result in short-term losses as the company grows its organization and invests in research, clinical trials, and other commercialization efforts. The company also expects that continued geographic expansion will be a key driver of growth in the near term.

Management Comments

• The company is focused on investing in manufacturing capacity, marketing, customer service, and sales force in multiple geographies to promote the use of our Motiva Implants.
• This expansion may result in short-term losses as we grow our organization and invest in research, clinical trials, and other commercialization efforts.
• We believe we can continue to grow market share in our existing markets due to the favorable safety profile and improved aesthetic outcomes of our Motiva Implants.
• We expect that continued geographic expansion will be a key driver of growth in the near term.

Industry Context

The document highlights Establishment Labs' position in the breast implant market, noting the relatively little innovation since the 1990s and the high complication rates of legacy breast implant options. The company positions its Motiva Implants as a safer and more natural alternative, aiming to capture market share by addressing patient concerns. The document also notes the global breast augmentation market is approximately 2.2 million procedures in 2022 and the global breast reconstruction market is expected to grow at a CAGR of 7.2% from 2023 to 2030.

Comparison to Industry Standards

• The document provides a table comparing the 10-year adverse event data of Sientra, Allergan, and Mentor, showing rupture rates of 8.5%, 9.3%, and 24.2%, respectively, capsular contracture rates of 12.9%, 18.9%, and 12.1%, respectively, and reoperation rates of 24.0%, 36.1%, and 25.5%, respectively.
• The company's post-market surveillance data indicates a rupture rate of less than 0.1%, a capsular contracture rate of less than 0.1%, and a reoperation rate for adverse events of less than 0.1%, which is significantly lower than the competitor data.
• The company's data is self-reported rather than collected at mandatory follow-ups and was generated solely for post-market surveillance instead of in connection with an FDA PMA study.
• The company's SmoothSilk surface is categorized in the smooth category, having a low roughness value of approximately 3.09 microns, which is significantly lower than the higher limit of the smooth surface clarification defined by ISO (< 10 microns).
• A 2021 published study in Nature Biomedical Engineering concluded that the SmoothSilk surface can largely suppress the foreign body response and fibrosis provoking the least amount of inflammation in comparison with the other commercially available surfaces.

Related Party Transactions

• The company recorded revenue of $1.2 million, $1.2 million and $1.4 million, respectively, for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of the Chief Executive Officer of the Company during the years ended December 31, 2023, 2022 and 2021.
• The company paid Dr. Chacn Quirs, the brother of the Companys Chief Executive Officer, approximately $0.4 million, $0.2 million and $0.4 million, respectively, for services rendered during the years ended December 31, 2023, 2022 and 2021.
• The company paid Ms. Gersh, a former board member, a consulting fee of $0.1 million during the years ended December 31, 2023 and 2022.
• The company granted Nicholas Lewin, a member of the board of directors, a stock option award for 7,829 options and a performance-based grant for 27,756 restricted stock units as compensation for consulting services.

Stakeholder Impact

• Shareholders may experience volatility in the share price due to the company's financial performance and market conditions.
• Employees may be affected by changes in the company's workforce and compensation structure.
• Customers may benefit from the company's innovative products and services.
• Suppliers may be affected by changes in the company's supply chain and manufacturing processes.
• Creditors may be affected by the company's debt obligations and financial performance.

Next Steps

• The company expects to commence manufacturing from the new facility in fiscal 2024.
• The company is awaiting FDA PMA approval of its Motiva Implants.
• The company will continue to invest in manufacturing capacity, marketing, customer service, and sales force in multiple geographies.
• The company will continue to seek out and pursue strategic acquisitions.

Key Dates

Keywords

breast implants, medical devices, Motiva Implants, aesthetics, reconstruction, FDA, clinical trials, manufacturing, regulatory approval, silicone, Mia Femtech, RFID technology